US filing the first worldwide for JT/GSK's MEK inhibitor for melanoma
This article was originally published in Scrip
Executive Summary
Japan Tobacco's trametinib has been filed for approval in the US by global licensee GlaxoSmithKline, for the treatment of unresectable or metastatic melanoma. The filing is the first to be made worldwide for the MEK inhibitor, JT in Japan told Scrip.
You may also be interested in...
Asia Deal Watch: RAPT And Hanmi Partner On CCR4 Antagonist Offering Potential In Multiple Cancer Types
RAPT can earn up to $108m in milestones plus sales royalties under the deal. BerGenBio, Piramal partner on developing AML therapy.
Daiichi’s EZH Contender Moves Ahead In Leukemia/Lymphoma
Japanese company starts pivotal trial with novel molecule as it looks to build oncology presence.
Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem
The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?
Need a specific report? 1000+ reports available
Buy Reports